InfectionNCT07511881
Far-UVC and Infections in Long-term Care Facilities
A study testing Far-uvc (222 nm) in people with Infection, run by Vejle Hospital at 1 site in Denmark.
Trial summary
Background Elderly residents in long-term care (LTC) facilities are highly susceptible to infections, often leading to hospitalizations and placing significant strain on the healthcare sector. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Infection
- What is being tested?
- Far-uvc (222 nm)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 635 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Nov 2024to 30 Apr 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Public LTC facilities in Vejle Municipality and the residents living in these facilities.
Who cannot join
- LTC facilities: 1) non-standardized buildings (building type or layout); 2) facilities with an increased risk of infections, such as those sharing common areas with kindergartens; and 3) facilities for individuals with dementia.
- Residents receiving respite care or living in assisted-living facilities.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Protocol for a Controlled, Phase II, Multi-arm, Parallel-group, Superiority, Six-month Trial Comparing the Effectiveness of Far-UVC (222 nm) in Two Experimental Arms Against Standard Care in Preventing Viral and Bacterial Infections in Long-term Care Facilities
Background Elderly residents in long-term care (LTC) facilities are highly susceptible to infections, often leading to hospitalizations and placing significant strain on the healthcare sector. The COVID-19 pandemic underscored the importance of airborne pathogen transmission and highlighted the necessity for targeted interventions that require minimal healthcare personnel resources to protect elderly populations. Far-UVC light has emerged as a promising technology offering both germicidal efficacy and safety for human exposure, although its clinical impact remains sparsely studied. This study aims to evaluate the effectiveness of far-UVC (222 nm) in mitigating hospitalizations due to viral and bacterial infections among LTC residents.
Methods The study is designed as a controlled, phase II, multi-arm, parallel-group, superiority, 6-month trial conducted in LTC facilities in Denmark. The LTC facilities will receive either far-UVC lamps or standard care with an allocation ratio of 1:1:10. One of the LTC facilities will be equipped with far-UVC lamps (experimental arm one) in common areas, while another will be equipped with far-UVC lamps (experimental arm two) in common areas and residents' apartments. We plan to include 12 public LTC facilities in Vejle with 542 residents. Outcome data will be obtained from nationally validated health registers. The primary outcome is LTC facility-acquired infections (lower respiratory tract infections, urinary tract infections, and bloodstream infections), which cause hospitalization. The key secondary outcome is prescribed antibiotics at LTC facilities, alongside monitoring all-cause mortality, cause-specific mortality (infection), and adverse events.
Discussion This trial aims to determine the clinical impact of far-UVC technology in LTC facilities. In the case of sufficiently promising effectiveness, a large-scale cluster randomized phase III will be carried out.
- Conditions
- Infection
- Being tested
- Far-uvc (222 nm), Standard Care (Treatment as Usual)
- Keywords
- Far-UVC; long-term care facilities; infections
- Medical subject headings
- Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Far-uvc (222 nm)Radiation
The far-UVC lamp that will be used in this study is a UV222™ lamp (UV Medico A/S, Denmark), which contains a krypton chloride excimer light source emitting filtered far-UVC irradiance at 222 nm and 60° angle. The optical filter (Care 222®, Ushio Inc., Japan) attenuates residual wavelength emission outside the 222-nm peak. The output is 115 mW, with a far-UVC irradiance of 13.7 µW/cm2 one meter from the lamp. The lamps will be configured to operate automatically in duty cycles to ensure that the threshold limit value (TLV) of 23 mJ/cm2 for the residents and personnel, as recommended by the International Commission on Non-ionizing Radiation Protection, is not exceeded. The UV222™ lamp carries a CE mark, which certifies its compliance with all European Union health and safety standards.
The lamps will be installed in the ceiling. The configuration of each lamp will depend on its location within the room, the size of the room, and the time of occupancy by the residents and personnel.
Standard Care (Treatment as Usual)Other
Standard Care (Treatment as Usual)
| Study group | Role | What they receive |
|---|---|---|
| Far-UVC lamps in common areas | Experimental | Not described Receives: Radiation: Far-uvc (222 nm) |
| Far-UVC lamps in common areas and residents' apartments | Experimental | Not described Receives: Radiation: Far-uvc (222 nm) |
| Standard care | Other | Not described Receives: Other: Standard Care (Treatment as Usual) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of hospitalisations due to respiratory tract infections acquired at long-term care facility
Measured: 6 months
Number of hospitalisations due to urinary tract infections acquired at long-term care facility
Measured: 6 months
Number of hospitalisations due to bloodstream infections acquired at long-term care facility
Measured: 6 months
Secondary outcomes (4)
Number of systemic antimicrobial agents prescribed for respiratory (excluding antivirals) infections at the long-term care facility
Measured: 6 months
Number of systemic antimicrobial agents prescribed for urinary tract infections at the long-term care facility
Measured: 6 months
Number of systemic antimicrobial agents prescribed for skin infections at the long-term care facility
Measured: 6 months
Number of systemic antimicrobial agents prescribed for other infections at the long-term care facility
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Apr 2026
- Study start1 Nov 2024
- Primary completion30 Apr 2025
- Study completion30 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 635 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vejle Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07511881
- Sponsor's protocol ID
- Far-UVC and infections
- Status last verified
- Mar 2026
- First submitted
- 30 Mar 2026
- Last updated
- 6 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Protocol for a Controlled, Phase II, Multi-arm, Parallel-group, Superiority, Six-month Trial Comparing the Effectiveness of Far-UVC (222 nm) in Two Experimental Arms Against Standard Care in Preventing Viral and Bacterial Infections in Long-term Care Facilities
- ClinicalTrials.gov ID
- NCT07511881
- Acronym / sponsor ID
- Far-UVC and infections
- Conditions
- Infection
- Keywords
- Far-UVC; long-term care facilities; infections
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 635 participants (actual)
- Lead sponsor
- Vejle HospitalUniversity, hospital or other
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 30 Apr 2025 (actual)
- Study completion
- 30 Apr 2025 (actual)
- First posted
- 6 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background Elderly residents in long-term care (LTC) facilities are highly susceptible to infections, often leading to hospitalizations and placing significant strain on the healthcare sector. The COVID-19 pandemic underscored the importance of airborne pathogen transmission and highlighted the necessity for targeted interventions that require minimal healthcare personnel resources to protect elderly populations. Far-UVC light has emerged as a promising technology offering both germicidal efficacy and safety for human exposure, although its clinical impact remains sparsely studied. This study aims to evaluate the effectiveness of far-UVC (222 nm) in mitigating hospitalizations due to viral and bacterial infections among LTC residents.
Methods The study is designed as a controlled, phase II, multi-arm, parallel-group, superiority, 6-month trial conducted in LTC facilities in Denmark. The LTC facilities will receive either far-UVC lamps or standard care with an allocation ratio of 1:1:10. One of the LTC facilities will be equipped with far-UVC lamps (experimental arm one) in common areas, while another will be equipped with far-UVC lamps (experimental arm two) in common areas and residents' apartments. We plan to include 12 public LTC facilities in Vejle with 542 residents. Outcome data will be obtained from nationally validated health registers. The primary outcome is LTC facility-acquired infections (lower respiratory tract infections, urinary tract infections, and bloodstream infections), which cause hospitalization. The key secondary outcome is prescribed antibiotics at LTC facilities, alongside monitoring all-cause mortality, cause-specific mortality (infection), and adverse events.
Discussion This trial aims to determine the clinical impact of far-UVC technology in LTC facilities. In the case of sufficiently promising effectiveness, a large-scale cluster randomized phase III will be carried out.
Study design
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Far-UVC lamps in common areas | Experimental | Radiation: Far-uvc (222 nm) |
| Far-UVC lamps in common areas and residents' apartments | Experimental | Radiation: Far-uvc (222 nm) |
| Standard care | Other | Other: Standard Care (Treatment as Usual) |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Public LTC facilities in Vejle Municipality and the residents living in these facilities.
Key exclusion criteria (2 listed)
- LTC facilities: 1) non-standardized buildings (building type or layout); 2) facilities with an increased risk of infections, such as those sharing common areas with kindergartens; and 3) facilities for individuals with dementia.
- Residents receiving respite care or living in assisted-living facilities.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Far-uvc (222 nm)The far-UVC lamp that will be used in this study is a UV222™ lamp (UV Medico A/S, Denmark), which contains a krypton chloride excimer light source emitting filtered far-UVC irradiance at 222 nm and 60° angle. The optical filter (Care 222®, Ushio Inc., Japan) attenuates residual wavelength emission outside the 222-nm peak. The output is 115 mW, with a far-UVC irradiance of 13.7 µW/cm2 one meter from the lamp. The lamps will be configured to operate automatically in duty cycles to ensure that the threshold limit value (TLV) of 23 mJ/cm2 for the residents and personnel, as recommended by the International Commission on Non-ionizing Radiation Protection, is not exceeded. The UV222™ lamp carries a CE mark, which certifies its compliance with all European Union health and safety standards. The lamps will be installed in the ceiling. The configuration of each lamp will depend on its location within the room, the size of the room, and the time of occupancy by the residents and personnel. | Radiation | Far-UVC lamps in common areas, Far-UVC lamps in common areas and residents' apartments |
| Standard Care (Treatment as Usual)Standard Care (Treatment as Usual) | Other | Standard care |
Primary outcome
Number of hospitalisations due to respiratory tract infections acquired at long-term care facility
Time frame: 6 months
Number of hospitalisations due to urinary tract infections acquired at long-term care facility
Time frame: 6 months
Number of hospitalisations due to bloodstream infections acquired at long-term care facility
Time frame: 6 months
4 secondary outcomes
Number of systemic antimicrobial agents prescribed for respiratory (excluding antivirals) infections at the long-term care facility
Time frame: 6 months
Number of systemic antimicrobial agents prescribed for urinary tract infections at the long-term care facility
Time frame: 6 months
Number of systemic antimicrobial agents prescribed for skin infections at the long-term care facility
Time frame: 6 months
Number of systemic antimicrobial agents prescribed for other infections at the long-term care facility
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Infection
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
RecruitingObservational study
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Hepatitis D
RecruitingObservational study
VIRal Pulmonary Infections in Older AGE
Viral Pulmonary Infections
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Far-uvc (222 nm) in people with Infection, run by Vejle Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of hospitalisations due to respiratory tract infections acquired at long-term care facility (time frame: 6 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2026.